Malignant Solid Tumor
51
9
14
21
Key Insights
Highlights
Success Rate
70% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
17.6%
9 terminated out of 51 trials
70.0%
-16.5% vs benchmark
0%
0 trials in Phase 3/4
48%
10 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 21 completed trials
Clinical Trials (51)
A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
A Clinical Study Comparing the Bioavailability of HRS-2189 Tablets
Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors
Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)
A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With Solid Tumour Malignancies
A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients